Selected documents from Propecia litigation were released by court order in 2021. This series walks through these documents, revealing Merck’s strategy for discounting safety concerns arising from clinical trials and adverse event reports. The collection is divided into three parts:
1. An inside look at the development of Propecia (1994–2001)
2. Merck responds to regulatory concerns (2006–2009)
3. Propecia lawsuits (2011–2020)
The source documents are available thanks to the efforts of Reuters Investigates, and hosted on the website of the Post-Finasteride Syndrome Foundation.
More on Merck
- Disinformation is a weapon in the war over finasteride safety
- How Merck buried finasteride’s full impact on chemical signaling
- Rules of engagement: how sensitive concerns are hidden from drug trials
- Polls vs. official data on side effect rates
- Hair or manhood—choose one?
- Meta-analysis launders safety data from old pharma trials; blames patients for drug harms
- How was finasteride invented?
- Merck’s Propecia business
- Since 1994, Merck has been aware of unresolved sexual dysfunction in men who stopped taking finasteride
- The Merck files, part 3: Propecia lawsuits